OR2AT1P

Across TCGA pan-cancer cohorts, OR2AT1P RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated OR2AT1P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OR2AT1P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated OR2AT1P expression acts as an unfavorable survival marker, although some lineages such as PAAD and ESCA show a favorable association.

LIHC, UCEC, and PAAD are the cancer types where OR2AT1P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.431	0.628	<.001	103	view →
UCEC	DFS	Tertile	III,IV	0.395	0.654	.001	54	view →
PAAD	OS	Tertile	All	0.793	0.483	.013	45	view →
KIRC	OS	Quartile	All	0.526	0.705	<.001	42	view →
PCPG	OS	Tertile	All	0.870	0.992	<.001	39	view →
CHOL	OS	Tertile	II,III,IV	0.201	0.700	.036	36	view →
ESCA	OS	Quartile	III,IV	0.753	0.334	.014	35	view →
UVM	DFS	Tertile	All	0.149	0.766	.001	27	view →
BRCA	OS	Tertile	IV	0.415	0.796	.023	18	view →
TGCT	OS	Tertile	All	0.880	0.976	.009	18	view →
PRAD	DFS	Tertile	All	0.959	0.872	.027	12	view →
SKCM	DFS	Quartile	II,III,IV	0.518	0.758	.003	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

OR2AT1P–LIHC (OS)

Open the LIHC breakdown →